Objective: Patients presenting for transcatheter aortic valve replacement are often in acute on chronic heart failure, as indicated by elevated N-terminal pro-B-type natriuretic peptide. Many believe that elevated N-terminal pro-B-type natriuretic peptide is an indication to treat medically, reserving surgery until the patient is medically optimized. Methods: A single-center transcatheter aortic valve replacement database was queried from December 2015 to November 2016 to identify patients undergoing transcatheter aortic valve replacement. Patients were divided into two cohorts based on preoperative N-terminal pro-B-type natriuretic peptide level. An analysis was then completed to assess outcomes such as length of intensive care unit stay, total length of stay, discharge to home, major complications, and mortality at 30 days. Results: There were 142 patients (median age = 80 years, 44% female) with preoperative N-terminal pro-B-type natriuretic peptide data included (range = 106-73,500 pg/mL). The mean Society of Thoracic Surgeons predicative risk of mortality was 8%, and 46 patients (32%) had N-terminal pro-B-type natriuretic peptide of greater than 3000 pg/mL. N-terminal pro-B-type natriuretic peptide of greater than 3000 pg/mL was associated only with increased intensive care unit length of stay of greater than 24 hours (35% vs 9%, P = 0.0001). There was no statistical difference between cohorts with regard to total length of stay of greater than 3 days (24% vs 15%, P = 0.2), discharge to home (74% vs 83%, P = 0.3), major complication, or mortality at 30 days. Conclusions: Transcatheter aortic valve replacement is an appropriate and effective treatment for patients with aortic stenosis presenting with high N-terminal pro-B-type natriuretic peptide and acute on chronic heart failure.
F
or the past decade, transcatheter aortic valve replacement (TAVR) has become a common treatment for patients with severe symptomatic aortic stenosis (AS). 1 Multiple studies have demonstrated TAVR to be noninferior to a traditional surgical approach in both high-and intermediate-risk patients populations. [1] [2] [3] [4] [5] In the United States, TAVR has been approved for use in highrisk patient populations since 2011 and has been used in intermediate-risk patient populations since 2016. [5] [6] [7] As we evaluate TAVR in low-risk patients, much is still to be learned about the optimal timing of treatment for patients with severe symptomatic AS.
Many preoperative TAVR patients present with acute on chronic congestive heart failure (CHF). Measuring blood levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) has become a method to diagnose acute CHF, as well as a marker for reduced left ventricular systolic function. 8 N-terminal pro-B-type natriuretic peptide is synthesized in ventricular cardiomyocytes and released when the cells are subjected to myocardial ischemia or stress.
9,10 N-terminal pro-B-type natriuretic peptide has been shown to be elevated both in patients with symptomatic and asymptomatic left ventricular dysfunction. 8, 11, 12 As an ageindependent approach for ruling out acute CHF, NT-proBNP values of less than 300 pg/mL have a 98% negative predictive valve. 13 Several previous studies have suggested that NT-proBNP levels can be effectively used as a predictor for complications after cardiac and noncardiac surgery. 10, [14] [15] [16] However, few studies comment on the predictive value of NT-proBNP levels in TAVR patient outcomes and no such studies involving data of either intermediate-risk patients or current valve technology. [17] [18] [19] [20] [21] Currently, it is common for TAVR candidates presenting with high NT-proBNP levels to be medically optimized or undergo balloon valvuloplasty, and valve replacement delayed until the acute heart failure exacerbation has resolved. In the present study, we retrospectively analyzed the records of 142 patients with AS in both intermediate-and high-risk populations undergoing elective TAVR at a single institution. Patients were stratified by level of NT-proBNP and postoperative results compared with determine whether NT-proBNP was an accurate predictive factor for outcomes.
METHODS
A single-center, retrospective review of a prospectively collected TAVR database was queried from December 2015 to November 2016 after institutional review board approval. All patients with severe AS that underwent elective TAVR and had preoperative NT-proBNP measured as part of routine preadmission testing were identified. Demographics, preoperative risk factors, frailty metrics, The Society of Thoracic Surgeons risk assessment, aortic valve measurements based on preoperative echocardiogram and cardiac gated computed tomography, and intraoperative anesthesia and valve type were assessed. The data were stratified in two study groups based on the preprocedure NT-proBNP level. All study patients had clinically significant AS and elevated NT-proBNP at baseline, with the majority of greater than 300 pg/mL, and the midpoint between the upper quartile and median valve of the cohort was established as the cutoff valve. An interquartile ranges value of 3000 pg/mL or less was chosen for the low NT-proBNP group and a value of greater than 3000 pg/mL for the high NT-proBNP group (see Table 1 ). The primary study end point was 30-day mortality. The secondary study end points were in-hospital complications, adjudicated according to the Valve Academic Research Consortium 2 criteria, as well as resource use parameters such as intensive care unit (ICU) hours, total length of stay (LOS), and discharge location to home. 22 The ICU LOS and overall LOS parameters were calculated in two different ways. First, we compared the median ICU hours and LOS between the high and low NT-proBNP groups. We also compared the two study groups by proportion of patients having ICU stay of greater than 24 hours and LOS of greater than 3 days. Differences between the high and low NT-proBNP groups were evaluated using nonparametric statistical tests (Kruskal-Wallis test) for continuous variables and Fisher exact test for categorical variables. All statistical analysis was conducted using SAS 9.4 software (SAS Institute, Inc, Cary, NC USA) and reported at 95% confidence interval level.
RESULTS
There were 142 patients (mean age = 88 years, 44% female) with recorded preoperative NT-proBNP levels (range = 106-73,500 pg/mL) in the database. All patients received a commercially available TAVR via a transfemoral approach. Of these patients, 32% (n = 42) were in the high NT-proBNP cohort. The high NT-proBNP cohort had many preoperative variables such as higher creatinine, lower albumin, increased previous myocardial infarction, increased atrial fibrillation/flutter, and lower left ventricular ejection fraction, consistent with a potentially sicker patient population ( Table 1 ). The mean Society of Thoracic Surgeons risk of mortality for the entire study was 8% but was statistically different between the two cohorts: low NT-proBNP 7% (range = 4.3%-9.5%) and high 9% (range = 7%-11%) (P = 0.003).
The primary end point, mortality at 30 days, was not statistically different between the low vs high NT-proBNP groups (2.1% vs 2.1%, P = 0.6). Secondary outcomes were also similar as were complications (Table 1) ; the patients in the low and high NT-proBNP cohorts were not statistically different regarding LOS of greater than 3 days (15% vs 23%, P = 0.2) or discharge location home (83% vs 74%, P = 0.3) (see Fig. 1 ). Low NT-proBNP and high NT-proBNP exhibited statistical differences only regarding increased ICU stay of greater than 24 hours (9% vs 32%, P = 0.0001) ( Table 2) .
DISCUSSION
Acute on chronic CHF is a common finding in patients presenting for treatment of severe symptomatic AS awaiting TAVR. Many centers delay surgery until the patient can be medically optimized in an effort to improve operative outcomes. Januzzi et al. 13 defined NT-proBNP of less than 300 pg/mL as a diagnostic threshold with 98% negative predicative valve for excluding acute CHF. A previous study conducted by Ayhan et al. 23 with a smaller patient population (n = 31) showed that TAVR can be safely and effectively performed on patients with high levels of NT-proBNP (average = 4633 pg/mL). Focusing on the interquartile range of our study population, a NT-proBNP level of greater than 3000 pg/mL was used to stratify our patient population. For these patients, NT-proBNP level may be a useful measurement of acute heart failure but should be considered with other factors for individual treatment. 8, 11, 19, 22 Our findings suggest that TAVR in patients with acute heart failure, as measured by elevated NT-ProBNP, may be safe. AV, aortic valve; CABG, coronary artery bypass graft; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, The Society of Thoracic Surgeons.
We found that patients with severe AS presenting with NT-proBNP levels of greater than 3000 pg/mL did not have higher 30-day mortality or complication rates and also did not experience an increased LOS, or less discharge to home, as compared with the lower NT-proBNP group. These finding contrasts with the prognostic ability of NT-proBNP for other operations and suggests that patients undergoing TAVR should be evaluated using different metrics. 10, [14] [15] [16] Previous studies regarding the prognostic value of NT-proBNP levels in TAVR patients are conflicting. 17, 20, 22 Riberiro et al. 24 studied 333 consecutive patients undergoing TAVR and found higher NT-proBNP levels (baseline cutoff level = 2000 pg/mL) were independently associated with increased cardiovascular mortality. Notably, their study population represented an earlier era and included a higher percentage of alternative access: 53.2% transapical and 7.5% transaortic TAVR. 24 Herein, we address this question using a large patient population in a modern approach with current day TAVR devices, 100% transfemoral and 90% completed under conscious sedation, and include intermediate-and high-risk candidates. In our study population, NT-proBNP had little prognostic ability with regard to outcome after TAVR.
Limitations of this study are inherent because of the retrospective and single-center design. In addition, this study is limited by the size of the patient population and potential for a type II error. Notably, we noted a difference between cohorts with regard to LOS in the ICU of greater than 24 hours, there was a higher percentage of patients who underwent moderate sedation TAVR in the low BNP group that could explain this difference. Findings in this study need to be confirmed by larger patient registries. Furthermore, the ability of this study to be generalized to a younger and lower-risk patient population is unclear.
In conclusion, initial medical therapy to treat acute heart failure before TAVR can increase the length of hospitalization and may be unnecessary. Although many factors need to be considered to accurately judge patient risk before TAVR, our findings suggest that NT-proBNP is not particularly useful. For severe symptomatic AS, TAVR is an effective and appropriate treatment for patients presenting with acute CHF, as determined by high levels of NT-proBNP, and should be considered in lieu of initial medical therapy for patients presenting with heart failure. Postoperative outcomes for low NT-proBNP (≤3000 pg/mL) and high NT-proBNP (>3000 pg/mL) patients. Outcomes compared as percent of patients within the cohort. Only ICU stay >24 hours was statistically different (P = 0.0001). ICU, intensive care unit; LOS, length of stay.
